Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Sanara MedTech Inc.NASDAQ: SMTI
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $43.77K (cash outflow) fell 97.5% year over year, behind the +56.2% change in trailing-twelve-month capital expenditures. Sequentially, it fell 46.7% from the prior quarter. Over 3 fiscal years it compounded at +83.6% a year.
Context
- Capital expenditures amounted to 4.5% of revenue in FY2025, up 4.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -97.5% toward the trailing-twelve-month pace of +56.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (4.63M) USD
- Year-over-year change
- -1917.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.63M) | -1917.3% |
| FY2024 | 2024-12-31 | (229.3K) | +13.6% |
| FY2023 | 2023-12-31 | (265.25K) | +64.5% |
| FY2022 | 2022-12-31 | (747.02K) | +0.5% |
| FY2021 | 2021-12-31 | (750.45K) | — |
Capital Expenditures vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +56.2% is the 4th highest of 10, against a peer median of +6.0%.
- Capital expenditures amounts to 2.7% of revenue for SMTI, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $31.21M USD | -33.9% | +20.4% | 10.9% | |
| LTM Jun 2026 | $29.4M USD | -11.5% | -4.4% | 3.8% | |
| LTM Apr 2026 | CA$10.14M CAD | -5.9% | +5.5% | 1.5% | |
| LTM Mar 2026 | $9.17M USD | +175.1% | -9.6% | 4.2% | |
| LTM Mar 2026 | $4.68M USD | -74.6% | -59.1% | 1.4% | |
| LTM Mar 2026 | $2.95M USD | +56.2% | +83.6% | 2.7% | |
| LTM Mar 2026 | $756K USD | +39.5% | -47.1% | 1.1% | |
| LTM Mar 2026 | $284K USD | +6.0% | -38.6% | 0.4% | |
| LTM Mar 2026 | $172K USD | +405.9% | -66.1% | 0.6% | |
| LTM Mar 2026 | $59K USD | +101.7% | -28.8% | 1.0% | |
| Peer median (excluding SMTI) | — | +6.0% | -28.8% | 1.4% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.99M) | (8.09M) | (4.44M) | (9.91M) | (27.66M) |
| Depreciation & Amortization | 596.98K | 2.37M | 3.68M | 4.92M | 28.56M |
| Deferred Income Tax | 0 | (5.84M) | 0 | 0 | 0 |
| Stock-Based Compensation | 2.67M | 2.7M | 3.44M | 4.44M | 718.71K |
| Change in Working Capital | (1.18M) | 517.62K | (3.28M) | (911.72K) | (3.84M) |
| Accounts Receivables | (774.81K) | (2.27M) | (1.73M) | (4.54M) | 4.03M |
| Inventory | (1.15M) | (517.27K) | (1.55M) | 1.44M | (431.33K) |
| Accounts Payables | 99.13K | (423.75K) | 575.15K | (471.21K) | 1.24M |
| Other Working Capital | 645.56K | 3.73M | (577.32K) | 2.66M | (8.68M) |
| Other Non-Cash Items | 1.1M | 2.79M | (2.64M) | 1.44M | 9.02M |
| Operating Cash Flow | (4.81M) | (5.55M) | (3.25M) | (23.78K) | 6.79M |
| Capital Expenditures | (750.45K) | (747.02K) | (265.25K) | (229.3K) | (4.63M) |
| Acquisitions (Net) | 0 | (2.52M) | (9.94M) | 0 | 0 |
| Purchases of Investments | (4.53M) | (250K) | 0 | (5.3M) | 9.48M |
| Sales of Investments | 0 | 0 | 0 | 0 | (2.96M) |
| Other Investing Activities | (578.59K) | (598.45K) | 650 | (1.1M) | (10.47M) |
| Investing Cash Flow | (5.28M) | (3.51M) | (10.21M) | (6.61M) | (8.36M) |
| Debt Repayment | 0 | 0 | 9.69M | 19.59M | 0 |
| Common Stock Issued | 28.94M | 0 | 911.37K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (642.53K) | (627.35K) | (958.59K) | (2.15M) | (8.48M) |
| Financing Cash Flow | 28.3M | (627.35K) | 9.64M | 17.37M | (8.48M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 18.2M | (9.69M) | (3.81M) | 10.73M | (10.03M) |
| Free Cash Flow | (5.56M) | (6.3M) | (3.51M) | (253.08K) | 2.16M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.